{"TopicDetails": {"type": 0, "ccm2Id": 31099127, "cftId": 0, "identifier": "JUST-2018-AG-DRUGS", "title": "Supporting Initiatives in the Field of Drugs Policy", "publicationDateLong": 1536019200000, "callIdentifier": "JUST-2018-AG-DRUGS", "callTitle": "Supporting Initiatives in the Field of Drugs Policy", "callccm2Id": 31099128, "allowPartnerSearch": true, "workProgrammepart": {"id": 266569, "ccm_id": 31093771, "wp_part": "JUST-2018", "wp_year": "JUST-2018", "wp_title": "JUST-2018", "wp_website": "http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/index.html", "wp_document": "http://ec.europa.eu/research/participants/data/ref/other_eu_prog/justice/wp/justice-awp-2018_en.pdf"}, "frameworkProgramme": {"id": 31070247, "abbreviation": "JUST", "description": "Justice Programme"}, "programmeDivision": [{"id": 31084407, "abbreviation": "JUST.1.1", "description": "Justice programme 2014-2020"}, {"id": 31070248, "abbreviation": "JUST.1", "description": "Justice programme 2014-2020"}, {"id": 31070252, "abbreviation": "JUST.1.1.4", "description": "Drugs"}], "topicMGAs": [], "tags": ["new psychoactive substances", "drug", "drugs", "online trade of drugs", "drugs policy"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "JUST-DRUGS-AG HOME Action Grant", "typeOfMGA": []}], "plannedOpeningDate": "04 September 2018", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["16 January 2019"]}], "latestInfos": [{"approvalDate": "Jan 10, 2019 9:35:45 AM", "lastChangeDate": "Jan 10, 2019 9:35:45 AM", "content": "<p>An updated Q&amp;A document has been published under the 'Additional documents' section.</p>"}, {"approvalDate": "Dec 21, 2018 4:25:11 PM", "lastChangeDate": "Dec 21, 2018 4:25:11 PM", "content": "<p>&nbsp;Q&amp;A document has been published under the 'Additional documents' section.</p>"}], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3276992": [{"action": "JUST-2018-AG-DRUGS - JUST-DRUGS-AG HOME Action Grant", "plannedOpeningDate": "04 September 2018", "deadlineModel": "single-stage", "deadlineDates": ["16 January 2019"], "budgetYearMap": {"2018": 2249000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2018"]}, "description": "<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The present Topic aims at funding projects in the area of EU drugs policy. Project applications submitted under the Topic must address at least one of the following priorities:</p><p>- to support activities in the area of epidemiology of use of new psychoactive substances, including potent synthetic opioids, as well as activities related to emerging drug problems including the online trade of drugs;</p><p>- to support the civil society organisations by reinforcing their (i) advocacy function, (ii) capacity to make a difference at the local level, (iii) best practice sharing methods;</p><p>- to support key stakeholders by expanding their knowledge and skills in the context of implementing minimum quality standards in drug demand reduction, particularly in the area of social integration;</p><p>- to promote practical application of drug-related research, and, in particular, addiction research with a view of addressing current challenges and new threats.</p><p>Any action under this Call for Proposals shall respect and shall be implemented in line with the rights and principles enshrined in the Charter of Fundamental Rights of the European Union. Applications should pay appropriate attention to the effects of the project on individual rights and freedoms, as well as to possible remedies. In addition, any action under this Call for Proposals should comply with all relevant ethical principles and all applicable international, EU and national law on ethical issues while carrying out the project.</p><p>This call will fund activities on:</p><p>\u2022 data collection, surveys and research activities;</p><p>\u2022 training activities;</p><p>\u2022 mutual learning, network development, identification and exchange of good practices, cooperation;</p><p>\u2022 events, conferences, expert meetings;</p><p>\u2022 dissemination and awareness-raising activities.</p><p>Type of Action: JUST-DRUG-AG</p>\n", "conditions": "<p><b><span style=\"font-size:9.0pt;line-height:115%;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\ncolor:#003366;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:\r\nAR-SA\">1.&nbsp;&nbsp; Eligible countries (plsease consult the <a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/justice/wp-call/justdrugs_call-proposals_ag-18_en.pdf\" target=\"_blank\">Call document </a>for all related details)<br />\r\n</span></b></p>\r\n<p class=\"MsoNormal\" style=\"text-align:justify;line-height:normal\"><span style=\"font-size:10.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\n&quot;Times New Roman&quot;;mso-fareast-language:EN-GB\">- the Member States of the European Union (including their overseas departments), except for Denmark and the United Kingdom;</span></p>\r\n<p class=\"MsoNormal\" style=\"text-align:justify;line-height:normal\"><span style=\"font-size:10.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\n&quot;Times New Roman&quot;;mso-fareast-language:EN-GB\">- Albania. </span></p>\r\n<p class=\"MsoNormal\" style=\"text-align:justify;line-height:normal\"><span style=\"font-size: 10pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;\">Proposals from  applicants in candidate or associated countries may be selected provided  that, on the date of award, agreements have entered into force setting  out the arrangements for the participation of those countries in the  programme.</span></p>\r\n<p>Should a  candidate or associated country join the programme during the call  process, a notification will be posted on the Participant Portal.</p>\n\n<p><b><span style=\"font-size:9.0pt;line-height:115%;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\ncolor:#003366;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:\r\nAR-SA\">2.&nbsp;&nbsp; General eligibility provisions:</span></b><span style=\"font-size:9.0pt;line-height:115%;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;\r\nmso-fareast-font-family:&quot;Times New Roman&quot;;color:black;mso-ansi-language:EN-GB;\r\nmso-fareast-language:EN-GB;mso-bidi-language:AR-SA\"> </span></p>\r\n<p><span style=\"font-family: Arial, sans-serif; font-size: 10pt;\">(a) &nbsp;Applications must be submitted no later than the deadline for submission as indicated on the Participant Portal</span></p>\r\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"font-size:10.0pt;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\nmso-fareast-language:EN-GB\">(b) &nbsp;Applications must be submitted in writing using the Electronic Submission System of the Participant Portal</span></p>\r\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"font-size:10.0pt;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\nmso-fareast-language:EN-GB\">(c) &nbsp;Applications must be submitted using  the standard Submission Form Part A and Part B. They must include all  the mandatory information and be accompanied by all the compulsory  Annexes</span></p>\r\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"font-size:10.0pt;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\nmso-fareast-language:EN-GB\">(d)&nbsp; Applications must be drafted in one of  the EU official languages (Note: for reasons of efficiency, the  Commission advises Applicants to use English)</span></p>\r\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"font-size:10.0pt;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\nmso-fareast-language:EN-GB\">(e) &nbsp;<span style=\"font-size:\r\n10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:Arial\">Projects  cannot be scheduled to last more than 24 months. Applications for  projects scheduled to run for a longer period will be rejected. </span></span></p>\r\n<p class=\"MsoNormal\" style=\"line-height:normal\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\n&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;\r\nmso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Failure to comply with the above requirements will lead to the rejection of the application.</span></p>\r\n<p class=\"MsoNormal\" style=\"line-height:normal\">&nbsp;</p>\r\n<p><b><span style=\"font-size:9.0pt;line-height:115%;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\ncolor:#003366;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:\r\nAR-SA\">3.&nbsp;&nbsp; Eligible applicants and applications:</span></b></p>\r\n<p><span style=\"font-size:10.0pt;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\nmso-fareast-language:EN-GB\"> </span></p>\r\n<p class=\"Text1\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:0cm\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;\r\nmso-bidi-font-family:Arial\">In order to be eligible for a grant the applicant and co-applicants must: </span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">a)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">be legal persons. </span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">b)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">be established in a country participating in the Justice Programme. </span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">c)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">International organisations may be established outside of the  Member States of the European Union participating in the Justice  Programme. </span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">d)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">be a public body or a non-profit-making private entity or an  international organisation. For-profit entities can only participate as  co-applicants. Union agencies cannot submit applications nor be  co-applicants. </span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">e)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">International organisations cannot submit applications; however they may participate as co-applicants. </span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">f)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">Applications must be transnational involving at least 2 entities  established in two different EU Member States participating in the  Justice Programme or one EU Member State and Albania. </span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">g)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">Proposals seeking EU co-funding of less than EUR 250 000 will be rejected. </span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo1;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">h)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">the project must not have started prior to the date of submission of the grant application.</span></p>\r\n<p class=\"Text1\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:0cm\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;\r\nmso-bidi-font-family:Arial\">Union agencies can be neither Applicants nor Co-applicants. </span></p>\r\n<p class=\"Text1\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:0cm\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;\r\nmso-bidi-font-family:Arial\">Affiliated entities, i.e. legal entities  having a legal or capital link with Applicants, shall take part in the  action as individual Co-applicants in order to declare eligible costs.</span></p>\r\n<p><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\n&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;\r\nmso-fareast-language:EN-US;mso-bidi-language:AR-SA\">To prove these  eligibility requirements, Applicants and Co-applicants will have to  provide the relevant information and upload necessary documents showing  their legal status in the Beneficiary Register.</span></p>\r\n<p>&nbsp;</p>\r\n<h2 style=\"margin-top:12.0pt;margin-right:0cm;margin-bottom:12.0pt;margin-left:\r\n1.0cm;text-indent:-1.0cm;mso-list:l0 level2 lfo1;tab-stops:49.65pt\"><b><span style=\"font-size:9.0pt;line-height:115%;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\ncolor:#003366;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:\r\nAR-SA\">4.&nbsp;&nbsp; Eligible activities:</span></b></h2>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:0cm;tab-stops:36.0pt\"><span style=\"font-size:10.0pt;font-family:\r\n&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:Arial\">The following types of activities are eligible under this <a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/justice/wp-call/justdrugs_call-proposals_ag-18_en.pdf\" target=\"_blank\">Call for Proposals</a>:</span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo2;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">a)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">data collection, surveys and research activities;</span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo2;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">b)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">training activities;</span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo2;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">c)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">mutual learning, network development, identification and exchange of good practices, cooperation;</span></p>\r\n<p class=\"Text2\" style=\"margin-top:0cm;margin-right:0cm;margin-bottom:6.0pt;\r\nmargin-left:36.0pt;text-indent:-18.0pt;mso-list:l1 level1 lfo2;tab-stops:42.55pt\"><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\nVerdana;mso-bidi-font-family:Verdana\"><span style=\"mso-list:Ignore\">d)<span style=\"font:7.0pt &quot;Times New Roman&quot;\">&nbsp;&nbsp; </span></span></span><span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-bidi-font-family:\r\nArial\">events, conferences, expert meetings;</span></p>\r\n<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  <span style=\"font-size:10.0pt;font-family:&quot;Verdana&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\n&quot;Times New Roman&quot;;mso-bidi-font-family:Arial;mso-ansi-language:EN-GB;\r\nmso-fareast-language:EN-US;mso-bidi-language:AR-SA\">e) dissemination and awareness-raising activities.</span></p>\r\n<p>&nbsp;</p>\n<h2 style=\"margin-top:12.0pt;margin-right:0cm;margin-bottom:12.0pt;margin-left:\r\n1.0cm;text-indent:-1.0cm;mso-list:l0 level2 lfo1;tab-stops:49.65pt\"><b><span style=\"font-size:9.0pt;line-height:115%;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\ncolor:#003366;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:\r\nAR-SA\">5. Evaluation criteria and process:<br />\r\n</span></b></h2>\r\n<p>Selection and Award criretia as well as the evaluation process are described in sections 7 and 8 of the <a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/justice/wp-call/justdrugs_call-proposals_ag-18_en.pdf\" target=\"_blank\">Call document</a>.</p>\r\n<p>&nbsp;</p>\n<p><b><span style=\"font-size:9.0pt;line-height:115%;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\ncolor:#003366;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:\r\nAR-SA\">6.&nbsp;&nbsp; Indicative timetable for evaluation and grant agreement:</span></b><span style=\"font-size:9.0pt;line-height:115%;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;\r\nmso-fareast-font-family:&quot;Times New Roman&quot;;color:black;mso-ansi-language:EN-GB;\r\nmso-fareast-language:EN-GB;mso-bidi-language:AR-SA\"> described in section 3 of the <a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/justice/wp-call/justdrugs_call-proposals_ag-18_en.pdf\" target=\"_blank\">Call document</a>.</span></p>\r\n<p>&nbsp;</p>\n<p><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\n&quot;Times New Roman&quot;;color:#003366;mso-fareast-language:EN-GB\">7.&nbsp;&nbsp; Proposal templates and model grant agreements (MGA):</span></b></p>\r\n<p><span style=\"font-size: 9pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;\"><span style=\"font-size: 9pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/common/justdrugs-isfp-isfb-amif_guide-applicants-18_en.pdf\" target=\"_blank\">Guide for applicants</a><br />\r\n</span><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/common/tpl/pt/justdrugs-isfp-isfb-amif_call-pt-18_en.pdf\" target=\"_blank\">Standard proposal template</a></span><span style=\"font-size: 9pt; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;\"><br />\r\n<a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/common/justdrugs-isfp-isfb-amif_mga-multi_en.pdf\" target=\"_blank\">Multi-beneficiary Model Grant Agreement</a><br />\r\n</span></p>\r\n<p>&nbsp;</p>\n<p>Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.</p>\n<p><b><span style=\"font-size:9.0pt;line-height:115%;\r\nfont-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\ncolor:#003366;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:\r\nAR-SA\">8.&nbsp;&nbsp; Additional documents:<br />\r\n</span></b><span style=\"font-size:9.0pt;\r\nline-height:115%;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;;\r\ncolor:black;mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:\r\nAR-SA\"><br />\r\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/justice/wp/justice-awp-2018_en.pdf\" target=\"_blank\">Annual</a></span><span style=\"font-size: 11pt; line-height: 115%; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;\"><span style=\"font-size: 9pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;\"><a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/justice/wp/justice-awp-2018_en.pdf\" target=\"_blank\"> Work Programme 2018</a><br />\r\n</span></span></p>\r\n<p><span style=\"font-size: 11pt; line-height: 115%; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;\"><span style=\"font-size: 9pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <a href=\"https://ec.europa.eu/research/participants/data/ref/other_eu_prog/justice/legal/justice-legalbasis_en.pdf\" target=\"_blank\">Justice Programme legal basis</a></span></span><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:\r\n&quot;Times New Roman&quot;;color:black;mso-fareast-language:EN-GB\"><br />\r\n</span></p>\r\n<p><span style=\"font-size: 11pt; line-height: 115%; font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;;\"><span style=\"font-size: 9pt; line-height: 115%; font-family: &quot;Arial&quot;,&quot;sans-serif&quot;;\">&nbsp;&nbsp;&nbsp; &nbsp; <a href=\"https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1532935024654&amp;uri=CELEX:32018R1046\" target=\"_blank\">EU Financial Regulation</a></span></span><br />\r\n&nbsp;</p>", "supportInfo": "<p>Contact the <strong>JUST-DRUGS helpdesk</strong> for further assistance related to the call, topics and the content of proposals <a href=\"mailto:HOME-DRUGS@ec.europa.eu\">HOME-DRUGS@ec.europa.eu</a>.<br />\r\n<br />\r\n<strong><a href=\"http://ec.europa.eu/research/participants/portal/desktop/en/support/faq.html#f05\">Participant Portal FAQ</a></strong> &ndash; Submission of proposals.<br />\r\n<br />\r\n<strong><a href=\"http://ec.europa.eu/research/participants/api/contact/index.html\">IT Helpdesk</a>&ndash; contact the IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals</strong>, etc.<br />\r\n<br />\r\n<strong><a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/index_en.htm\">H2020 Online Manual</a> - Please use the manual with caution and only for the Participant Portal tools guidance</strong>, i.e. Submission service and Beneficiary register, because it is H2020 specific and does not cover the Justice Programme rules. Some aspects of the Justice Programme are different from the provisions of the H2020 programme.</p>", "sepTemplate": "<p>To access the Electronic Sumission Service, please click on the submission-button next to the type of action that corresponds to your proposal. You will then be asked to confirm your choice of the type of action and topic, as these cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Participant Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [{"callId": 52392599018, "id": 165886169, "title": "Questions and answers", "sectionId": 52392599018, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 202809, "docPath": "https://ec.europa.eu/info/funding-tenders/opportunities/docs/cap/just/just-2018-ag-drugs/1840132-q_a_final_updated_en.pdf", "id": 1840132, "fileName": "Q&A final_updated_en.pdf", "common": false, "crc32": 4209225660}]}], "infoPackDossiers": [], "callDetailsJSONItem": {"staticAdditionalInfo": "<p>The specific objective of this Call for proposals is to support projects in the field of drugs policy as regards judicial cooperation and crime prevention aspects closely linked to the general objective of the Programme, in so far as they are not covered by the Instrument for financial support for police cooperation, preventing and combating crime, and crisis management, as part of the Internal Security Fund, or by the third Programme for the Union's action in the field of health (2014-2020).</p>\n", "latestInfos": [{"approvalDate": "Jan 10, 2019 9:35:45 AM", "lastChangeDate": "Jan 10, 2019 9:35:45 AM", "content": "<ul>\r\n    <li>\r\n    <p>An updated Q&amp;A document has been published under the 'Additional documents' section of the topic JUST-2018-AG-DRUGS - Supporting Initiatives in the Field of Drugs Policy</p>\r\n    </li>\r\n</ul>"}, {"approvalDate": "Dec 21, 2018 4:25:11 PM", "lastChangeDate": "Dec 21, 2018 4:25:11 PM", "content": "<ul>\r\n    <li>\r\n    <p>Q&amp;A document has been published under the 'Additional documents' section of the topic JUST-2018-AG-DRUGS - Supporting Initiatives in the Field of Drugs Policy</p>\r\n    </li>\r\n</ul>"}, {"approvalDate": "Oct 9, 2018 3:39:03 PM", "lastChangeDate": "Oct 9, 2018 3:39:03 PM", "content": "<ul>\r\n    <li>\r\n    <p><span style=\"color: rgb(255, 0, 0);\"><span lang=\"EN-US\" style=\"font-family: Calibri, sans-serif; font-size: 11pt;\">Montenegro </span></span><span lang=\"EN-US\" style=\"color: rgb(31, 73, 125); font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;; font-size: 11pt; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: &quot;Times New Roman&quot;; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">joined the EU Justice programme on 13/09/2018 and<span style=\"color: rgb(255, 0, 0);\"> is </span><span style=\"color: rgb(255, 0, 0);\">an eligible country</span> under this call.</span></p>\r\n    </li>\r\n    <li>\r\n    <p><span lang=\"EN-US\" style=\"color: rgb(31, 73, 125); font-family: &quot;Calibri&quot;,&quot;sans-serif&quot;; font-size: 11pt; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: &quot;Times New Roman&quot;; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">The <span style=\"color: rgb(255, 0, 0);\">deadline </span>for submission has been extended to <span style=\"color: rgb(255, 0, 0);\">16 January 2019</span>; 17:00 (Brussels time)&nbsp;&nbsp;</span></p>\r\n    </li>\r\n</ul>"}, {"approvalDate": "Oct 9, 2018 3:07:23 PM", "lastChangeDate": "Oct 9, 2018 3:07:23 PM", "content": "The submission session is now available for: JUST-2018-AG-DRUGS(JUST-DRUGS-AG)"}, {"approvalDate": "Sep 4, 2018 12:30:00 AM", "lastChangeDate": "Sep 4, 2018 12:30:00 AM", "content": "The submission session is now available for: JUST-2018-AG-DRUGS(JUST-DRUGS-AG)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}